BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Muthana MM, Du X, Liu M, et al. (2023) CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment. Elife. 12 |
| Bailey C, Wei Y, Yan J, et al. (2023) Genetic and pharmaceutical targeting of HIF1α allows combo-immunotherapy to boost graft vs. leukemia without exacerbation graft vs. host disease. Cell Reports. Medicine. 101236 |
| Magenau JM, Jaglowski SM, Uberti J, et al. (2023) A Phase 2 Trial of CD24Fc for Prevention of Graft-vs-Host Disease. Blood |
| Wu X, Srinivasan P, Basu M, et al. (2023) CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma. Frontiers in Immunology. 14: 1176370 |
| Wu H, Ding P, Wu J, et al. (2023) A New Online Dynamic Nomogram: Construction and Validation of a Predictive Model for Distant Metastasis Risk and Prognosis in Patients with Gastrointestinal Stromal Tumors. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract |
| Liu Y, Zheng P. (2023) CD24-Siglec interactions in inflammatory diseases. Frontiers in Immunology. 14: 1174789 |
| Liu Y, Jie X, Nian L, et al. (2023) A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells. Frontiers in Immunology. 14: 1169071 |
| Muthana MM, Du X, Liu M, et al. (2023) CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment. Biorxiv : the Preprint Server For Biology |
| Liu M, Wang X, Du X, et al. (2023) Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy. Science Translational Medicine. 15: eabm5663 |
| Ding P, Wu J, Wu H, et al. (2023) Inflammation and nutritional status indicators as prognostic indicators for patients with locally advanced gastrointestinal stromal tumors treated with neoadjuvant imatinib. Bmc Gastroenterology. 23: 23 |